Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

Phase II Gleevec Idiopathic Hypereosinophilic Syndrome

This study has been withdrawn prior to enrollment.
(Withdrawn by PI due to insufficient accrual)
Sponsor:
Collaborator:
Novartis
Information provided by:
Stanford University
ClinicalTrials.gov Identifier:
NCT00230334
First received: September 28, 2005
Last updated: April 11, 2011
Last verified: April 2011
  Purpose

The purpose of the trial is to determine the safety and efficacy of Gleevec" in idiopathic hypereosinophilic syndrome (HES) and to characterize the molecular basis for the therapeutic benefit of Gleevec" in HES.


Condition Intervention Phase
Eosinophilia
Hypereosinophilic Syndrome
Drug: Gleevec
Phase 2

Study Type: Interventional
Study Design: Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: Phase II Study of Gleevec (Imatinib Mesylate) in Patients With Idiopathic Hypereosinophilic Syndrome (HES)

Resource links provided by NLM:


Further study details as provided by Stanford University:

Primary Outcome Measures:
  • To determine the hematologic response rate of imatinib in patients with HES.

Estimated Enrollment: 25
Study Start Date: June 2003
  Eligibility

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:- At study entry, absolute peripheral blood eosinophil count greater than upper limit of normal at the laboratory where the analysis is performed.

  • Patients must have symptomatic disease, e.g. signs or symptoms of organ involvement related to eosinophilia. Examples include pulmonary, cardiac, GI, or central nervous system disease, hepatomegaly, splenomegaly, or skin disease.
  • BCR-ABL-negative by PCR.
  • Patients are imatinib-naive.
  • Ability to understand and the willingness to sign a written informed consent document.
  • Ability to swallow capsules.
 Exclusion Criteria:- Pregnant or nursing women. Patients of childbearing potential must have a negative pregnancy test prior to initiation of study drug. Male and female patients of reproductive potential must agree to employ an effective barrier method of birth control during the study and for 3 months following discontinuation of study drug.
  • Serum creatinine >2.0.
  • Total serum bilirubin >2.0 mg/dl. AST(SGOT) and ALT (SGPT) more than 2.5 x the upper limit of normal range (ULN) at the laboratory where the analyses is performed.
  • Presence of clonal T-lymphocyte population by PCR or southern blotting.
  • ECOG Performance Status Score > or = to 3.
  • Busulfan within 6 weeks of starting treatment.
  • IFN-a within 14 days of starting treatment.
  • Low dose cytosine-arabinoside or vincristine within 14 days of starting treatment.
  • Hydroxyurea within 1 day of starting treatment.
  • Prednisone or other immunosuppressives (e.g. azathioprine, cyclosporine-A) within 14 days of starting treatment.
  • AML/ALL-type induction chemotherapy within 4 weeks of starting treatment
  • Persistent peripheral blood count toxicity of grade 2 or higher after receiving AML/ALL-type induction chemotherapy.
  • Treatment with other investigational agents within 28 days of starting treatment.
  • History of non-compliance to medical regimens.
  • Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure (Grade 3 / 4 New York Heart Association Criteria), unstable angina pectoris or cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements.
  • History of HIV-positivity.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00230334

Sponsors and Collaborators
Stanford University
Novartis
Investigators
Principal Investigator: Steven Edward Coutre Stanford University
  More Information

No publications provided

ClinicalTrials.gov Identifier: NCT00230334     History of Changes
Other Study ID Numbers: HEMMPD0001, HEMMPD0001
Study First Received: September 28, 2005
Last Updated: April 11, 2011
Health Authority: United States: Institutional Review Board
United States: Food and Drug Administration

Additional relevant MeSH terms:
Hypereosinophilic Syndrome
Eosinophilia
Syndrome
Disease
Hematologic Diseases
Leukocyte Disorders
Pathologic Processes
Imatinib
Antineoplastic Agents
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action
Pharmacologic Actions
Protein Kinase Inhibitors
Therapeutic Uses

ClinicalTrials.gov processed this record on November 20, 2014